Ababneh HS et al. Leaving lytic lesions–Is there new role of radiation in multiple myeloma in the CAR T era? Pract Radiat Oncol 2022;12(5):367-9. Abstract

Bernstein ZS et al. Bone disease in multiple myeloma: Biologic and clinical implications. Cells 2022;11(15):2308. Abstract

Caro J et al. How to treat high-risk myeloma in diagnosis and relapse. Am Soc Clin Oncol Educ Book 2021;41:291-309. Abstract

Lei MM et al. Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma. Leuk Lymphoma 2022;63(13):3249-52. Abstract

Perrot A et al. Meaningful changes in patient-reported outcomes in relation to best clinical response and disease progression: Post hoc analyses from MAIA. ASH 2021;Abstract 4095.

Raje NS et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group. Lancet Haematol 2022;9(2):e143-61. Abstract

Shapiro YN et al. Lifestyle considerations in multiple myeloma. Blood Cancer J 2021;11(10):172. Abstract

Terpos E et al. Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study. Blood Adv 2021;5(3):725-36. Abstract

Waldschmidt JM et al. Nivolumab-based salvage therapy to restore T cell fitness in penta-refractory multiple myeloma with relapse to anti-BCMA CAR T cell therapy. ASH 2022;Abstract 4456.

Yee AJ, Raje N. Minimal residual disease in multiple myeloma: Why, when, where. Hematology Am Soc Hematol Educ Program 2021;2021(1):37-45. Abstract